title: Imaging of prostate cancer.
abstract: The role of imaging in the diagnosis and management of prostate is reviewed. Transrectal ultrasonography, which can be used to guide biopsy, is most frequently used imaging technique in cancer detection. For determining the extent of disease, CT and MR imaging are the most commonly used modalities; bone scintigraphy and positron emission tomography have roles only in advanced disease. Currently, the role of imaging in prostate cancer is evolving to improve disease detection and staging, to determine the aggressiveness of disease, and to predict outcomes in different patient populations
authors.affiliation: Weill Medical College of Cornell University, New York, NY, USA. akino@mskcc.org
authors.forename: Oguz
authors.initials: O
authors.lastname: Akin
authors.forename: Hedvig
authors.initials: H
authors.lastname: Hricak
mesh_terms: D000367:Age Factors; D000368:Aged; D000911:Antibodies, Monoclonal; D001707:Biopsy, Needle; D001859:Bone Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000556:secondary; D005500:Follow-Up Studies; D006801:Humans; D007202:Indicators and Reagents; D008207:Lymphatic Metastasis / Q000175:diagnosis / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000175:diagnosis; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D010808:Physical Examination; D049268:Positron-Emission Tomography; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D012372:ROC Curve; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014463:Ultrasonography
chemical_list: D000911:Antibodies, Monoclonal; D007202:Indicators and Reagents; C101315:Capromab Pendetide; D017430:Prostate-Specific Antigen